Adenovirus Therapy for Pancreatic Cancer
Author Information
Author(s): Toyoda Eiji, Doi Ryuichiro, Kami Kazuhiro, Mori Tomohiko, Ito Daisuke, Koizumi Masayuki, Kida Atsushi, Nagai Kazuyuki, Ito Tatsuo, Masui Toshihiko, Wada Michihiko, Tagawa Masatoshi, Uemoto Shinji
Primary Institution: Kyoto University, Japan
Hypothesis
Can a midkine promoter-based conditionally replicative adenovirus effectively target and treat midkine-expressing pancreatic cancer?
Conclusion
Ad5MK has an anti-tumor effect against human pancreatic cancer cell lines that express midkine mRNA.
Supporting Evidence
- Midkine mRNA expression was significantly stronger in pancreatic cancers than in non-cancerous pancreatic tissues.
- Ad5MK showed much greater cytotoxicity for midkine-expressing cell lines than for midkine-negative cell lines.
- In vivo studies showed that mice treated with Ad5MK survived significantly longer than those treated with control groups.
Takeaway
This study shows that a special virus can help kill pancreatic cancer cells that have a specific marker called midkine.
Methodology
The study involved examining midkine expression in pancreatic cancer cell lines and tissues, assessing adenoviral transduction efficiency, and evaluating the anti-tumor effects in vitro and in vivo.
Limitations
The study only tested a single dose of the adenovirus and did not explore optimal dosing strategies.
Participant Demographics
22 patients with pancreatic cancer who underwent pancreatectomy.
Statistical Information
P-Value
0.0002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website